Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
62.76
-1.98 (-3.06%)
At close: Sep 18, 2026, 4:00 PM EDT
62.74
-0.02 (-0.03%)
After-hours: Sep 18, 2026, 7:51 PM EDT
Travere Therapeutics Employees
Travere Therapeutics had 497 employees as of December 31, 2025. The number of employees increased by 112 or 29.09% compared to the previous year.
Employees
497
Change (1Y)
112
Growth (1Y)
29.09%
Revenue / Employee
$1,189,799
Profits / Employee
-$87,453
Market Cap
5.92B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 497 | 112 | 29.09% |
| Dec 31, 2024 | 385 | 5 | 1.32% |
| Dec 31, 2023 | 380 | -82 | -17.75% |
| Dec 31, 2022 | 462 | 152 | 49.03% |
| Dec 31, 2021 | 310 | 48 | 18.32% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| Mirum Pharmaceuticals | 433 |
| Rhythm Pharmaceuticals | 414 |
| CRISPR Therapeutics AG | 393 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
| CG Oncology | 142 |
| Definium Therapeutics | 106 |
TVTX News
- 2 days ago - Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum - Business Wire
- 8 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 10 days ago - Travere Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 weeks ago - Travere Therapeutics price target raised to $68 from $49 at Piper Sandler - TheFly
- 5 weeks ago - Travere Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 5 weeks ago - Travere Therapeutics price target raised to $78 from $68 at Evercore ISI - TheFly
- 6 weeks ago - Travere Therapeutics price target raised to $75 from $61 at Wedbush - TheFly
- 6 weeks ago - Travere Therapeutics price target raised to $70 from $62 at Canaccord - TheFly